INTRODUCTION

H
epatitis B virus (HVB) infection is a worldwide epidemic that, in addition to the liver, causes damage in other organs. HBV-membranous nephropathy (HBV-MN) is the most common renal manifestation in patients with HBV infection, [1] [2] [3] possibly linked to subepithelial deposits of viral immune complexes. 4, 5 HBV RNA and DNA were detected in glomerular and tubular cells, although a pathogenetic role for these viral nucleic acids remains to be confirmed. 6 The effects of vaccination programs on the decline of HBVassociated MN, particularly in Asian and African children, 7, 8 further support a possible relationship between HBV infection and MN. 9 Identification in 2009 of PLA2R as the major antigen associated with idiopathic membranous nephropathy provided the first diagnostic biomarker. 10 The 2 available assays (immunofluorescence test assay [IFTA] and enzyme-linked immunosorbent assay) for the detection of circulating anti-PLA2R antibodies (PLA2R-Abs) have shown that PLA2R-Abs are a specific and sensitive biomarker of MN, being detected in 70% to 80% of patients with primary MN worldwide in early serum samples, and consistently absent in healthy individuals and in patients with other nephropathies or autoimmune diseases. 11 Because anti-PLAR antibody levels fluctuate and can rapidly decrease under immunosuppressive treatment, detection of PLA2R antigen in subepithelial immune deposits of patients with MN is even more sensitive than serology.
12,13 Although Hoxha et al.
suggested that the diagnosis between primary MN and secondary MN could rely on the presence or absence of PLA2R antigen in the immune deposits, 14 other investigators showed that the antigen could be detected in cases of active sarcoidosis, 15, 16 hepatitis C virus, 17 and HBV infection-associated MN. 13, 18 In the Chinese population, 25 of 39 patients (64%) with HBV-MN had deposited subepithelial PLA2R antigen, and all tested sera contained anti-PLA2R antibody. 18 These findings suggest that HBV infection could be the trigger of autoimmunity anti-PLA2R.
Whatever the mechanism of autoimmunity, we are facing the conundrum of antiviral versus immunosuppressive therapy with the risk of aggravating the viral infection. Most data have been obtained in smallscale case series published before the availability of anti-PLA2R antibody assays, and a standard of care has not yet been established. 19, 20 Here, we report the first 2 cases in which rituximab was used after controlling viral replication.
CASE PRESENTATION Case 1
A 44-year-old man of Moroccan origin presented at Dijon University Hospital in October 2012 with lowerextremity edema and lower chest pain. His medical history was unremarkable. His lungs were clear with decreased ventilation at the bases. Blood pressure was 155/117 mm Hg. Urinary dipstick showed 3þ proteinuria. Laboratory studies revealed a serum creatinine of 1.0 mg/dl (92 mmol/l), urine protein-to-creatinine ratio of 11 g/g, serum albumin of 1.3 g/dl (13 g/l), and normal liver test results. Ultrasound examination revealed thrombosis of the left renal vein, and angiography showed bilateral lung emboli. Active HBV infection was diagnosed: viral load was 2.7 log with positivity for HBs antigen, anti-HBc, and anti-HBe antibody; HBe antigen and anti-HBs antibody were negative (Table 1) . PLA2R-Abs were measured at 333 RU/ml by enzyme-linked immunosorbent assay. PLA2R-Ab IgG4 was the prevailing subclass (IgG4 > IgG3 > IgG1 > IgG2) of antiÀPLA2R-Abs measured by IFTA (see Supplementary Material). Tests for antinuclear antibody (ANA), antineutrophil cytoplasmic antibody (ANCA), and rheumatoid factor were negative. Serum complement levels (C3, C4, and CH50) were normal. The patient was treated for 4 months with antivitamin K, entecavir, and a combination of angiotensin-converting enzyme inhibitor, calcium channel blocker, a-adrenergic blocker, and diuretic.
During this time period, he maintained heavy proteinuria and high levels of PLA2R-Abs (Figure 1a) , although viral replication became undetectable in January 2013 about 2 months after entecavir.
The patient was then referred in April 2013 to our Nephrology Department at the Tenon Hospital for a transjugular kidney biopsy before starting rituximab. The clinical situation was unchanged. Laboratory investigations revealed a serum creatinine of 0.84 mg/dl (74 mmol/l), estimated glomerular filtration rate (eGFR) by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation of 105 ml/min per 1.73 m 2 , urine protein-to-creatinine ratio of 13 g/g, serum albumin of 2.4 g/dl (24 g/l), and normal urinary sediment. HBV load was undetectable. The kidney biopsy specimen showed a type-1 MN with mildly thickened basement membranes, thin mesangial stalks, and normal interstitium with < 5% fibrosis (see Supplementary Material). There was no endocapillary proliferation or crescent. Immunofluorescence examination showed diffuse granular membranous deposits of IgG, C3, and both light-chain isotypes. Staining for C1q and fibrinogen was negative; rare subepithelial deposits of IgA without IgM were seen. Subclass analysis showed mostly IgG4 deposits with low amounts of IgG3, in perfect agreement with the results of the IFTA assay of circulating PLA2R-Abs (Figure 2a and b) . PLA2R staining of the biopsy specimen was also strongly positive ( Figure 2c ). Detection of HbS, HbC, and Hbe antigens were negative (Figure 2d , e, and f). By electron microscopy, subepithelial electron-dense deposits were observed, without any organization or viral particle aspect (Figure 2g and h) .
Six months after initiation of antiviral therapy and 4 months after negative viral load, the patient received 2 infusions of rituximab (375 mg/m 2 ) at a 1-week interval while antiviral treatment was continued at the same dose. Immunological remission (undetectable anti-PLA2R antibody) was achieved 17 days after the first rituximab infusion, together with a marked decrease of 24-hour proteinuria (3.28 g/g) ( Figure 1a ). Antiviral treatment was stopped in August 2014. On last followup, in February 2016, daily proteinuria was 0.15 g, serum albumin was 3.7 g/dl (37g/l), and serum creatinine was 0.81 mg/dl (71 mmol/l); there was no viral replication. Viral reactivation (2.96 log; 5346 copies) was noted in May 2017.
Case 2
The second patient was a 26-year-old man from the Republic of Benin who presented in April 2014 with bilateral lower-extremity edema since 1 month. He had a previous medical history of malaria and HBV infection since 2009 without any treatment. Laboratory studies revealed serum creatinine of 1.11 mg/dl (98 mmol/l), serum albumin of 1.77 g/dl (17.7g/l), urine protein-to-creatinine ratio of 7.4 g/d, and PLA2R-Ab at 1/50 by IFTA. The kidney biopsy showed a type-2 MN, with thickened basement membranes and diffuse subepithelial deposits and spikes, but a normal interstitium with < 5% fibrosis. Immunofluorescence examination revealed diffuse, granular membranous deposits of IgG, C3, and both light-chain isotypes. Staining for C1q and fibrinogen was negative; no subepithelial deposits of IgA and IgM were seen. Subclass analysis showed mostly IgG4 deposits with low amounts of IgG2. PLA2R staining was strongly positive. Detection of HbS, HbC, and HBe antigens was negative (Table 1) . Active HBV infection was confirmed (733 copies/ml). Angiotensin-converting enzyme inhibitors and entecavir were started at the end of April 2014 (Figure 1b) . HBV-DNA became undetectable since November 2014. Because of fluctuating levels of anti-PLA2R antibodies in the first trimester of 2015, the patient received 2 infusions of rituximab (375 mg/m 2 ) at a 1-week interval, and subsequently achieved immunological and Table 1 . Distinct teaching points Hepatitis B should be added to the list of potential diseases associated with PLA2R-related membranous nephropathy.
It is likely that active viral infection triggers auto-immunity against PLA2R.
Antiviral treatment should be the first-line therapy.
Rituximab can be used safely and efficiently in patients with controlled viral infection who have not reached immunological remission (defined by disappearance of anti-PLA2R antibodies).
Antiviral therapy should be associated with rituximab and continued for several months after completion of immunosuppressive therapy because of risk of reactivation of the viral infection.
Further studies are needed to understand how hepatitis B virus triggers the production of anti-PLA2R antibodies.
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DISCUSSION
The association of a viral infection and an auto-immune disease is a therapeutic conundrum because of the risk of aggravation of the viral infection with immunosuppressive agents. In children, HBV-associated MN has a favorable prognosis with high spontaneous remission rate with antiviral drugs; however, in adults, resolution of proteinuria is uncommon, and patients who do not clear the virus usually develop progressive renal failure. 20 Because of the poor tolerance of interferon and of the toxicity of adefovir, entecavir and tenofovir (the latter particularly in co-infected HIV patients) are the most commonly used. This report first shows the efficacy and safety of rituximab. In case 1, in which MN remained immunologically and clinically active after 6 months of antiviral treatment despite full control of viral replication, rituximab appeared to have a dramatic effect. Because the patient was cured by antiÀB-cell therapy, not by efficient antiviral therapy, one can hypothesize that PLA2R immunization played a critical role in the pathogenesis of the disease. This hypothesis is supported by the parallel, spectacular decrease of proteinuria and anti-PLA2R antibody after rituximab infusion. However, these data do not exclude a role for HBV infection in the triggering of PLA2R autoimmunization. In case 2, in which rituximab was infused in a period of fluctuation of PLA2R-Ab titer, we suggest that rituximab helped consolidation of immunological remission followed by clinical remission.
The relationship between HBV infection and MN remains unclear. We detected subepithelial PLA2R deposits without HBV antigens in our 2 patients. The absence of deposited HBV antigens contrasting with previous literature, 5,21,22 although we used the same source of anti-HBV antibodies, might be explained by the use of a very stringent technique to avoid interaction of the test antibody specific for HBV antigens with deposited IgG. Our observations in Africans confirm those made in a Chinese population, in which 64% of patients with HBV-MN also had PLA2R antigen in immune deposits. 18 The mechanisms whereby HBV may trigger autoimmunity may involve molecular mimicry, alterations of regulatory T-cells (Treg), or Bcell activation. 23, 24 HBV scanning of protein databases has revealed regional similarities between HBV proteins and antigenic targets of nuclear and smooth muscle antibodies. 25 Alignment of the immunodominant peptide of PLA2R against a database of microbial proteins identified a small sequence shared by a cell wall enzyme, D-alanyl-D alanine carboxypeptidase, common in several bacterial strains, including Clostridia species, but no mimicry of HBV viral antigens. 26 No direct link between Treg number and/or function and HBVrelated immunopathological manifestations has been reported. 23 Little is known about the effect of chronic HBV infection on B-lymphocytes, although there is evidence that HBV is present in these cells. 27 Very importantly, rituximab associated with entecavir did not induce a viral reactivation or alterations of liver test results. Rituximab is safe, provided that viral replication is under control and that antiviral therapy is continued to avoid a burst of viral replication. 28 Longterm surveillance of the viral status is warranted, because reactivation can occur well after completion of immunosuppressive therapy. The current recommendation of stopping antiviral prophylaxis 6 to 12 months after the cessation of chemotherapy may not fully protect all patients from HBV reactivation, as indicated by our case 1. The optimal duration of follow-up needs to be determined, and until better guidelines are set, there is no choice but to keep monitoring patients for reactivation for as long as possible. 29 Furthermore, we do not yet know whether the antiviral/rituximab strategy used (successfully) in these 2 cases would also be safe in individuals highly expressing cccDNA in the liver or pgRNA in the blood. 30 In conclusion, these case reports suggest a link between HBV infection and MN through induction of PLA2R autoimmunization. Antiviral therapy should first be used to control viral infection. This treatment can subsequently be associated with rituximab in cases in which immunological activity monitored with anti-PLA2R antibody persists after control of viral replication. Antiviral therapy should be continued for a long time after completion of immunosuppressive treatment.
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